OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. 

Biotechnology

Health Care

Life Sciences

Therapeutics

OrsoBio

G. Mani Subramanian

Alex Nguyen

Steve Weng

Gans Ganapati

Ryan Huss

Rob Myers

OrsoBio

Org chart

Teams

Similar companies